Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Cullinan Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Cullinan Therapeutics, Inc.

CGEM

Cullinan Therapeutics, Inc.

About Cullinan Therapeutics, Inc.

Cullinan Therapeutics is a biopharmaceutical company focused on developing targeted immunology and oncology therapies. Its pipeline includes clinical-stage candidates like CLN-978 for autoimmune diseases, and CLN-619, CLN-049, and CLN-617 for various cancers. The company leverages innovative biologics, collaborates with partners, and holds extensive intellectual property rights to address unmet medical needs in autoimmune disorders and cancer markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Cullinan Therapeutics, Inc.

1
1
Cullinan Therapeutics, Inc. Cullinan Therapeutics Reports $49.7 Million Net Loss in Q1 2026

Via official filing (AI summary) | 30 days ago | 0 comments

2
1
Cullinan Therapeutics, Inc. Cullinan Therapeutics Reports $219.9M Net Loss and Updates on Clinical Pipeline

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Cullinan Therapeutics, Inc. Cullinan Therapeutics Reports $50.6 Million Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Cullinan Therapeutics, Inc. Cullinan Therapeutics Reports $70.1 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Cullinan Therapeutics, Inc. Cullinan Therapeutics Reports $48.5 Million Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Cullinan Therapeutics, Inc. Cullinan Therapeutics Reports Improved Financial Position, Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments